肝がん治療薬市場：タイプ別、流通チャネル別-2025-2030年の世界予測

肝がん治療薬市場は、2023年に8億6,670万米ドルと評価され、2024年には9億8,760万米ドルに達すると予測され、CAGR 14.04%で成長し、2030年には21億7,453万米ドルに達すると予測されています。

肝がん治療薬の調査対象範囲には、化学療法、免疫療法、標的療法、最近承認された遺伝子療法など、肝臓がんの治療、予防、管理に使用される医薬品が含まれます。この拡大する市場は、肝臓がんの罹患率の増加、医療技術の進歩、意識の高まりによって需要が高まっています。肝がんは依然として世界のがん死亡の主要原因の1つであるため、効果的な治療が急務となっています。最終用途は病院、外来手術センター、腫瘍クリニックに及び、主に医療提供者と患者が関与しています。市場開拓は、研究開発への旺盛な投資、新規治療法の承認、製薬大手、バイオテクノロジー企業、学術機関との共同研究によって左右されます。個別化医療、コンパニオン診断、ラジオ波焼灼術のような非侵襲的治療法の開発にはビジネスチャンスがあります。事業拡大に熱心な企業は、革新的な医薬品を迅速に導入するため、FDAやEMAの承認経路に注目すべきです。チャンスはあるもの、課題としては、高い研究コスト、厳しい規制要件、新薬に伴う潜在的な副作用などが挙げられます。市場の限界は、競合情勢と希少肝がんサブタイプの患者数が限られていることに起因しており、採用を拡大するには患者中心のアプローチと費用対効果の高い治療法が必要です。治療効果と患者の転帰を改善するために、分子プロファイリングとバイオマーカー探索を革新のターゲットにすることができます。併用療法の調査や既存の治療法の最適化も潜在的な成長経路となります。肝がん治療薬市場は、急速な進歩と強力な競合を特徴とするダイナミックな市場であり、事業成長を維持するための適応戦略が求められています。標的ドラッグデリバリーシステムを重視し、医薬品開発における予測分析にAIを活用することで、市場の潜在力をさらに活用し、利害関係者が機会と制約の両方を効果的に活用できるようにすることができると思われます。

市場力学：急速に進化する肝がん治療薬市場の主要市場インサイトを公開

肝がん治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 肝臓がんの有病率の上昇
  • 肝がんに関する啓発活動の増加
  • 精密医療の急速な導入と標的療法の出現
• 市場抑制要因
  • 開発コストの高さ
• 市場機会
  • 肝がん治療薬に対する継続的な規制当局の承認
  • 新薬開発のための研究開発投資の拡大
• 市場の課題
  • 肝がん治療薬の副作用

ポーターの5つの力：肝がん治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、肝がん治療薬市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：肝がん治療薬市場における外部からの影響の把握

外部マクロ環境要因は、肝がん治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析肝がん治療薬市場における競合情勢の把握

肝がん治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス肝がん治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、肝がん治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨肝がん治療薬市場における成功への道筋を描く

肝がん治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 肝臓がんの罹患率の上昇
    • 肝臓がんに関する啓発活動の強化
    • 精密医療の急速な導入と標的療法の出現
  • 抑制要因
    • 肝がん治療薬の開発コストが高い
  • 機会
    • 肝がん治療薬の規制承認が進行中
    • 新薬開発のための研究開発投資の増加
  • 課題
    • 肝がん治療薬の副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 肝がん治療薬市場：タイプ別

• 免疫療法
• 標的療法

第7章 肝がん治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第8章 南北アメリカの肝がん治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の肝がん治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの肝がん治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Celsion Corporation
• Eisai Co., Ltd.
• Eli Lilly and Company
• Exelixis, Inc.
• F. Hoffmann-La Roche Ltd
• Lion TCR Pte. Ltd.
• Merck & Co., Inc.
• Novartis AG
• Ono Pharmaceutical Co., Ltd.
• Sanofi S.A.

LIST OF FIGURES

• FIGURE 1. LIVER CANCER DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. LIVER CANCER DRUGS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. LIVER CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. LIVER CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. LIVER CANCER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL LIVER CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. LIVER CANCER DRUGS MARKET DYNAMICS
• TABLE 7. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY IMMUNO THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL LIVER CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 17. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 19. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 21. CANADA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. CANADA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES LIVER CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 28. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. CHINA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. CHINA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. INDIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. INDIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. INDONESIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. MALAYSIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. PHILIPPINES LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. SINGAPORE LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. TAIWAN LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. THAILAND LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. VIETNAM LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA LIVER CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 58. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. ISRAEL LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. ITALY LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. ITALY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. NORWAY LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. POLAND LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. POLAND LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. QATAR LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. QATAR LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. SWITZERLAND LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. TURKEY LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM LIVER CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. LIVER CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 101. LIVER CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

The Liver Cancer Drugs Market was valued at USD 866.70 million in 2023, expected to reach USD 987.60 million in 2024, and is projected to grow at a CAGR of 14.04%, to USD 2,174.53 million by 2030.

The scope of research on liver cancer drugs encompasses pharmaceuticals used for treatment, prevention, and management of liver cancer, including chemotherapy, immunotherapy, targeted therapy, and recently approved gene therapy options. This expanding market sees rising demand driven by increasing liver cancer incidence, advancements in medical technology, and growing awareness. The necessity lies in the urgent need for effective treatments as liver cancer remains one of the leading causes of cancer mortality globally. Applications span hospitals, ambulatory surgical centers, and oncology clinics, with end-use sectors primarily involving healthcare providers and patients. Market growth is influenced by robust investment in research and development, approval of novel therapies, and collaborations between pharmaceutical giants, biotechnology firms, and academic institutions. Opportunities arise in the development of personalized medicine, companion diagnostics, and non-invasive treatment options like radiofrequency ablation. Companies keen on expansion should focus on the FDA and EMA approval pathways to swiftly introduce innovative drugs. Despite opportunities, challenges include high research costs, stringent regulatory requirements, and potential side effects associated with new drugs. Market limitations are driven by the competitive landscape and the limited patient population for rare liver cancer subtypes, necessitating patient-centric approaches and cost-effective therapies to increase adoption. Innovations can target molecular profiling and biomarker discovery to improve treatment efficacy and patient outcomes. Researching combination therapies and optimizing existing treatments also offers potential growth pathways. The liver cancer drug market remains dynamic, characterized by rapid advancements and strong competition, demanding adaptive strategies to sustain business growth. Emphasizing targeted drug delivery systems and harnessing AI for predictive analytics in drug development could further leverage market potential, ensuring stakeholders navigate both opportunities and constraints effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Liver Cancer Drugs Market

The Liver Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of liver cancer
  • Increasing initiatives for the awareness regarding liver cancer
  • Rapid adoption of precision medicine and emergence of targeted therapies
• Market Restraints
  • High cost for developing liver cancer drugs
• Market Opportunities
  • Ongoing regulatory approvals for the liver cancer drugs
  • Growing R&D investments for the development of novel drugs
• Market Challenges
  • Adverse side effects of liver cancer drugs

Porter's Five Forces: A Strategic Tool for Navigating the Liver Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Liver Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Liver Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Liver Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Liver Cancer Drugs Market

A detailed market share analysis in the Liver Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Liver Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Liver Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Liver Cancer Drugs Market

A strategic analysis of the Liver Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Liver Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Celsion Corporation, Eisai Co., Ltd., Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd, Lion TCR Pte. Ltd., Merck & Co., Inc., Novartis AG, Ono Pharmaceutical Co., Ltd., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Liver Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Immuno Therapy and Targeted Therapy.
• Based on Distribution channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of liver cancer
    • 5.1.1.2. Increasing initiatives for the awareness regarding liver cancer
    • 5.1.1.3. Rapid adoption of precision medicine and emergence of targeted therapies
  • 5.1.2. Restraints
    • 5.1.2.1. High cost for developing liver cancer drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing regulatory approvals for the liver cancer drugs
    • 5.1.3.2. Growing R&D investments for the development of novel drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse side effects of liver cancer drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Liver Cancer Drugs Market, by Type

• 6.1. Introduction
• 6.2. Immuno Therapy
• 6.3. Targeted Therapy

7. Liver Cancer Drugs Market, by Distribution channel

• 7.1. Introduction
• 7.2. Hospital Pharmacy
• 7.3. Online Pharmacy
• 7.4. Retail Pharmacy

8. Americas Liver Cancer Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Liver Cancer Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Liver Cancer Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. AstraZeneca PLC
• 4. Bayer AG
• 5. Bristol-Myers Squibb Company
• 6. Celsion Corporation
• 7. Eisai Co., Ltd.
• 8. Eli Lilly and Company
• 9. Exelixis, Inc.
• 10. F. Hoffmann-La Roche Ltd
• 11. Lion TCR Pte. Ltd.
• 12. Merck & Co., Inc.
• 13. Novartis AG
• 14. Ono Pharmaceutical Co., Ltd.
• 15. Sanofi S.A.